Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer

El-Ashmawy, Nahla E.; Hussien, Fatma Zakaria; El-Feky, Ola A.; Hamouda, Sara Mohamed; Al-Ashmawy, Ghada M.

doi:10.1016/j.lfs.2020.118193

Cited by 42 publications

(29 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunotherapy and targeted therapy have emerged as potential treatment methods for breast cancer [ 4 ]. Multiple targets have been identified such as vascular endothelial growth factor, epithelial membrane protein 2, long noncoding RNAs, and so on [ 5 , 6 ]. However, more therapeutic targets are also urgently needed.…”

Section: Introductionmentioning

confidence: 99%

ANKRD22 enhances breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression

Liu

Gong

et al. 2020

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Breast cancer is one of the most prevalent malignancies in women worldwide. Although great progress has been achieved in the diagnosis and treatment of breast cancer, the prognosis of patients with breast cancer is still poor due to distal recurrence and metastasis after surgery. This study demonstrated that the expression level of ankyrin repeat domain 22 (ANKRD22) in human breast cancer tissues was significantly higher than that in normal breast tissues. ANKRD22 knockdown inhibited the proliferation, invasion, and epithelial-mesenchymal transition (EMT) of breast cancer cells. Further research indicated that ANKRD22 regulated the expression of nucleolar and spindle-associated protein 1 (NuSAP1) and then the activation of Wnt/β-catenin signaling pathway. Moreover, overexpression of NuSAP1 reversed the inhibitory effects of ANKRD22 knockdown on the proliferation, invasion, and EMT of breast cancer cells. In summary, this study demonstrated that ANKRD22 enhanced breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression, which might shed light on new therapeutic approaches for breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

ANKRD22 enhances breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression

Liu

Gong

et al. 2020

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…LncRNAs have proved their important role in the pathogenesis of breast cancer 32,33 . FAM83H‐AS1 is one of the lncRNAs implicated in breast cancer 34 . Among 796 dysregulated lncRNAs, FAM83H‐AS1 showed the highest expression in breast cancer tissues (luminal subtype) in comparison to their adjacent normal tissues.…”

Section: Fam83h‐as1 Dysregulation In Human Cancersmentioning

confidence: 99%

Long non‐coding RNA FAM83H‐AS1 as an emerging marker for diagnosis, prognosis and therapeutic targeting of cancer

El-Ashmawy

Al-Ashmawy

Hamouda

2020

Cell Biochemistry & Function

Self Cite

View full text Add to dashboard Cite

Incidence and mortality rates of cancer continue to increase greatly despite the improved diagnostic and therapeutic methods. Based on GLOBOCAN estimates, the numbers of new cancer cases reported in 2018 were ~18.1 million, while the numbers of cancer mortalities were ~9.6 million. It remains difficult to diagnose most cancer patients at early stages. Although cancer therapy market is rapidly evolving, the effectiveness of therapy is still inadequate. Therefore, exploring new biomarkers for diagnosis, prognosis and treatment is essential for cancer management. Long non‐coding RNAs (lncRNAs) are unique regulatory molecules that control several cellular processes and are implicated in diverse human diseases including cancer. LncRNAs could serve as potential biomarkers for cancer patients to aid diagnosis and determine prognosis. In addition, numerous lncRNAs have proved their ability to predict response to cancer treatment. FAM83H antisense RNA 1 (FAM83H‐AS1) is among those highly dysregulated lncRNAs in cancer. FAM83H‐AS1 was demonstrated to participate in the progression of different malignancies and also shown to play a vital role in diagnosis, prognosis and treatment. Here, we analyse recent studies concerning the oncogenic role and molecular mechanisms of lncRNA FAM83H‐AS1 in the following cancer types: bladder, breast, lung, hepatocellular, colorectal, gastric, pancreatic, ovarian, cervical cancer as well as glioma.

show abstract

“…Samples of serum were prepared by standing the samples at room temperature to clot for 5-10 minutes and were centrifuged at 1,000× g for 10 minutes and were kept at -20°C till the time of biochemical analysis. 8 Also, 24-hour urine samples were collected. Blood glucose, serum creatinine, and 24-hour urine albumin were assessed by commercial kits purchased from Biodiagnostic Co., Egypt, using Shimadzu® (Japan) Spectrophotometer.…”

Section: Laboratory Investigationsmentioning

confidence: 99%

Copeptin: Promising Biomarker for Nephropathy in Type II Diabetes

Ali

Al-Ashmawy

Aboelnasr

et al. 2020

Journal of Advanced Medical and Pharmaceutical Research

View full text Add to dashboard Cite

Kidney injury is a dangerous diabetic microvascular complication responsible for the mortality of diabetics, which would require biomarkers for early detection of diabetic nephropathy. Copeptin, the C-terminal portion of vasopressin prohormone, is rapidly released in severe endogenous stress. So, the current work was carried out to evaluate and estimate copeptin as a marker for diabetic nephropathy. This cross-sectional work was conducted on 60 female and male type II diabetic cases. Diabetic cases were divided as normoalbuminuric (urinary albumin was <30 mg/24 h) without nephropathy and macroalbuminuric (urinary albumin was >300 mg/24 h) with nephropathy. The Control group was designated from fifteen matched healthy subjects. Controls and patients were evaluated for fasting blood glucose, glycosylated hemoglobin (HbA1c), urinary albumin, serum creatinine, and serum copeptin. Copeptin concentrations were significantly increased in type II diabetics with macroalbuminuria comparing to healthy controls and diabetics with normoalbuminuria. Serum copeptin concentrations were correlated positively with gold standard urinary albumin, serum creatinine, and HbA1c. Higher serum copeptin concentration in type II diabetics particularly in diabetics with nephropathy and its correlation with urinary albumin and HBA1c reflect the potential role of copeptin as a predictor of diabetes mellitus and development of diabetic nephropathy among type II diabetics considering other risk factors.

show abstract

Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer

Cited by 42 publications

References 45 publications

ANKRD22 enhances breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression

ANKRD22 enhances breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression

Long non‐coding RNA FAM83H‐AS1 as an emerging marker for diagnosis, prognosis and therapeutic targeting of cancer

Copeptin: Promising Biomarker for Nephropathy in Type II Diabetes

Contact Info

Product

Resources

About